Zhejiang Cancer Hospital
🇨🇳China
Combined Treatment of Treated Bile Duct Cancer
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05911425
Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05903456
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT05896059
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05856383
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 89
- Registration Number
- NCT05813626
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Multi-omics Study of Tongue Coating in Malignant Tumors of Digestive Tract
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 20000
- Registration Number
- NCT05794841
- Locations
- 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China
A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma
Recruiting
- Conditions
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05705583
- Locations
- 🇨🇳
An Zhao, Hangzhou, China
Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2023-01-03
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 184
- Registration Number
- NCT05669807
A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 174
- Registration Number
- NCT05669092
- Locations
- 🇨🇳
Zhengjiang Cancer Hospital, Hangzhou, Zhejiang, China
PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC Patients
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 220
- Registration Number
- NCT05651802
- Locations
- 🇨🇳
Sun Yat-sen University, Cancer Center, Guangzhou, Guangdong, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
© Copyright 2024. All Rights Reserved by MedPath